Reliant Glycosciences, LLC is a biotechnology company that focuses on developing diagnostic and prognostic tools for patients with IgA nephropathy. IgA nephropathy is a common kidney disease affecting more than 150,000 Americans. Reliant was spun-out in 2016 from UAB. The Reliant founders formed to address the unmet need and demand for disease-specific biomarkers to aid in development of disease specific therapies. Reliant’s goal is to develop marketable assays for these IgAN-specific biomarkers so that they can be available to the IgAN research community as well as pharmaceutical companies interested in developing treatments for IgAN. Reliant's goal is to have an impact on the disease itself and it's treatment.